Thompson Rahsaan 4

4 · ZEVRA THERAPEUTICS, INC. · Filed Feb 2, 2026

AI-generated summary of this filing

Updated Feb 2, 2026

Zevra Therapeutics (ZVRA) Rahsaan Thompson Sells Shares

What Happened

Rahsaan Thompson, Chief Legal & Compliance (Secretary) of Zevra Therapeutics (ZVRA), reported multiple transactions tied to equity awards and an open‑market sale. On Jan 30, 2026 he sold 4,080 shares in the open market at a weighted average price of $8.83 for total proceeds of $36,010.
Related to equity awards, the filing shows derivative activity: 11,333 shares were recorded as exercised/converted (acquired) and 11,333 shares were recorded as disposed at $0.00 (derivative), consistent with RSU settlement and shares withheld for taxes. The filing also reports grants on Jan 29, 2026 of 37,500 and 75,000 derivative awards (RSUs and/or option grants) at $0.00.

Key Details

Dates & prices: Open‑market sale 4,080 shares on 2026-01-30, weighted avg price $8.83 (trades ranged $8.58–$9.04). Exercise/conversion and derivative settlements recorded 2026-01-30; grants dated 2026-01-29. Report filed 2026-02-02.
Proceeds: Sale reported as $36,010. Some shares from vesting were withheld/disposed at $0.00 (tax withholding/settlement).
Shares owned after transaction: Not specified in the supplied summary of the Form 4.
Notable footnotes: F1 = each RSU converts to one share; F2 = 10b5‑1 plan adoption date 3/27/2025 (sale likely under a trading plan); F3 = sale executed in multiple trades; F4/F6 = RSU vesting schedule (one‑third vested/settled on Jan 30, 2026; remaining vest in annual installments); F5 = stock option grant vests over four years.
Timeliness: Filed on 2026-02-02 for transactions on 2026-01-29/30—appears timely under Form 4 reporting rules.

Context

This filing combines a routine open‑market sale with award activity. The derivative entries indicate RSUs/options vested and were settled; some of the settled shares were sold in the market while others were withheld/disposed (reported at $0) likely for taxes. The sale was executed under a 10b5‑1 plan (adopted 3/27/2025), which is a pre‑arranged trading plan commonly used to avoid timing questions.
These types of filings are factual records of insider transactions and do not by themselves indicate the insider’s view of the company’s prospects.

Form 4

Period: 2026-01-29

Chief Legal & ComplianceOther

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-01-30+11,333→ 53,999 total
Sale
Common Stock
[F2][F3]
2026-01-30$8.83/sh−4,080$36,010→ 49,919 total
Award
Restricted Stock Unit
[F1][F4]
2026-01-29+37,500→ 37,500 total
→ Common Stock (37,500 underlying)
Award
Stock Option (right to buy)
[F5]
2026-01-29+75,000→ 75,000 total
Exercise: $8.86Exp: 2036-01-28→ Common Stock (75,000 underlying)
Exercise/Conversion
Restricted Stock Unit
[F1][F6]
2026-01-30−11,333→ 22,667 total
→ Common Stock (11,333 underlying)

Footnotes (6)

[F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
[F2]Adoption date of referenced 10b5-1(c) plan is: 3/27/2025.
[F3]This transaction was executed in multiple trades at prices ranging from $8.58 to $9.04. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
[F4]The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date.
[F5]Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.
[F6]One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting Person's continued service through such vesting date.

Signature

/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Rahsaan W. Thompson|2026-02-02

1 file